Literature DB >> 7950815

Involvement of superior mesenteric vessels and portal vein in pancreatic adenocarcinoma: detection with CT during arterial portography.

P Soyer1, D Lacheheb, A Belkacem, M Levesque.   

Abstract

A prospective study was designed to determine the utility of computed tomography (CT) during arterial portography (CTAP) in the detection of superior mesenteric vessels and portal vein involvement in patients with pancreatic adenocarcinoma. Eighteen patients with adenocarcinoma of the head of the pancreas and eight patients with benign pancreatic disease were investigated with CTAP, dynamic contrast-enhanced CT, and angiography. Appropriate review was made to determine presence or absence of superior mesenteric vessels and portal vein involvement. Final diagnosis was obtained in all cases by surgical explorations. The overall accuracy rate for detecting or excluding superior mesenteric vessels and portal vein involvement was 96% (25 of 26 patients) with CTAP, 88% (23 of 26 patients) with dynamic contrast-enhanced CT, and 85% (22 of 26 patients) with angiography. No statistically significant difference in accuracy was found among the three techniques. Our results suggest that the use of CTAP is not indicated in the preoperative detection of superior mesenteric vessels and portal vein involvement in patients with pancreatic adenocarcinoma.

Entities:  

Mesh:

Year:  1994        PMID: 7950815     DOI: 10.1007/BF00206927

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  16 in total

1.  Prospective controlled trial of transhepatic biliary endoprosthesis versus bypass surgery for incurable carcinoma of head of pancreas.

Authors:  P C Bornman; E P Harries-Jones; R Tobias; G Van Stiegmann; J Terblanche
Journal:  Lancet       Date:  1986-01-11       Impact factor: 79.321

2.  Cancer of the head of the pancreas: an institutional review with emphasis on surgical therapy.

Authors:  J M Rosenberg; J P Welch; W P Macaulay
Journal:  J Surg Oncol       Date:  1985-03       Impact factor: 3.454

3.  The surgical treatment of pancreatic carcinoma.

Authors:  M Trede
Journal:  Surgery       Date:  1985-01       Impact factor: 3.982

Review 4.  Cancer of the pancreas.

Authors:  J M Howard; G L Jordan
Journal:  Curr Probl Cancer       Date:  1977-09       Impact factor: 3.187

5.  Computed tomographic appearance of resectable pancreatic carcinoma.

Authors:  Y Itai; T Araki; A Tasaka; M Maruyama
Journal:  Radiology       Date:  1982-06       Impact factor: 11.105

Review 6.  Experience with 647 consecutive tumors of the duodenum, ampulla, head of the pancreas, and distal common bile duct.

Authors:  F Michelassi; F Erroi; P J Dawson; A Pietrabissa; S Noda; M Handcock; G E Block
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

Review 7.  Pancreatic adenocarcinoma: designing the examination to evaluate the clinical questions.

Authors:  A J Megibow
Journal:  Radiology       Date:  1992-05       Impact factor: 11.105

8.  Preoperative staging and assessment of resectability of pancreatic cancer.

Authors:  A L Warshaw; Z Y Gu; J Wittenberg; A C Waltman
Journal:  Arch Surg       Date:  1990-02

9.  Comparison of CT and angiography in assessing resectability of pancreatic carcinoma.

Authors:  S Z Jafri; A M Aisen; G M Glazer; C A Weiss
Journal:  AJR Am J Roentgenol       Date:  1984-03       Impact factor: 3.959

10.  Fine-needle aspiration biopsy: pancreatic and biliary tumors.

Authors:  M A Hall-Craggs; W R Lees
Journal:  AJR Am J Roentgenol       Date:  1986-08       Impact factor: 3.959

View more
  3 in total

Review 1.  Pancreatic adenocarcinoma: why and when should it be resected?

Authors:  D Ravichandran; C D Johnson
Journal:  Postgrad Med J       Date:  1997-08       Impact factor: 2.401

2.  CT arterial portography in the staging of pancreatic malignancy.

Authors:  S Varshney; C N Hacking; C D Johnson
Journal:  Int J Pancreatol       Date:  2000-08

Review 3.  CT during arterial portography.

Authors:  P Soyer
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.